Business Wire

New Report Reveals Alarming Decline in Women’s Cancer Testing Worldwide

Share

Women’s cancer testing has declined globally, according to the latest Hologic Global Women’s Health Index, one of the largest collections of data on women’s health and well-being.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250121461870/en/

Hologic, Inc. (Nasdaq: HOLX), a leading women’s health innovator, partners with Gallup to create the Index. Now in its fourth year, the Index raises new concerns about declining trends in women’s health. For the first time in the history of the Index, women’s cancer testing declined: Only 10% of women surveyed worldwide said they were tested for any type of cancer in the past year, down two percentage points from the first two years of the Index.

This year’s Index will be released today during an event convened by Goals House, a community focused on driving progress toward the United Nations (UN) Sustainable Development Goals (SDGs) alongside the World Economic Forum in Davos, Switzerland. The event will feature a panel including Dr. Natalia Kanem, Executive Director of the United Nations Population Fund (UNFPA), Dr. Sania Nishtar, CEO, Gavi, The Vaccine Alliance and Elissa Miolene, Global Development Reporter, Devex.

“Today’s data reveal a worsening trend in women’s health,” said Stephen P. MacMillan, Chairman, President and CEO of Hologic. “The shocking decline in cancer testing is a wake-up call. Business as usual is not working. Innovative strategies and collaborative efforts are needed to make sustained improvements in women’s health and well-being around the world.”

Key findings from this year’s Index:

  • Cancer Screening Among Women Declined: Only 10% of women said they underwent any type of cancer testing in the past year, reflecting a decrease of two percentage points from the first two years of the survey.
  • Women Are Struggling More to Meet Basic Needs: A staggering 38% of women reported being unable to afford food at some point in the past year, marking the highest level of food insecurity in nearly two decades. And 32% of women said they could not afford adequate shelter.
  • More Women Are Worried and Sad: More women reported feeling worried (42%) and sad (30%) compared to Year 1 of the Index. And over one third (35%) said they felt unsafe in their communities.
  • Ongoing Physical Pain and Health Issues:34% of women reported experiencing significant pain the previous day, while 26% indicated that health problems impacted their ability to engage in everyday activities.
  • HIV Testing Rates for Women Are Alarmingly Low: The Index assessed women’s HIV testing for the first time and found concerning disparities: Less than0.5% of women were tested in certain countries, primarily those in the Middle East and North Africa, and no country scored above 41%. Globally, the percentage is much lower. Just 6% of women — regardless of whether they visited a healthcare professional or were tested for STIs — said they were tested for HIV in the past year.
  • Signs of Hope — Some Countries Are Making Progress:28 countries saw meaningful increases in their Index scores since the first year of the Index, including Kazakhstan, Kenya, Poland and Venezuela.

The Index assigns a women’s health score to each country or territory based on survey responses on five dimensions of health. Overall, the world scored 53 out of 100 on the Index in Year 4, reflecting no significant change since the Index started.

Taiwan led the world for the fourth consecutive year, scoring 68 out of a possible 100. Other top scores went to Kuwait (67), Austria (66) and Switzerland (65). The lowest scores went to Afghanistan (30), the Democratic Republic of Congo (34) and Chad (35). The United States scored 60 – on par with New Zealand (60) and Lithuania (60) – and fell seven places from its ranking in the third year of the Index to 37 out of 142 countries and territories.

The Index fills a critical gap in knowledge about the health, safety and well-being of women worldwide. Based on interviews with more than 146,000 women and men in 142 countries and territories, it represents the voices of 97% of the world’s women and girls aged 15 and older.

To see the full Index and related resources, visit WomensHealthIndex.com.

About Hologic, Inc.

Hologic, Inc. is a global leader in women’s health, dedicated to developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. For more information on Hologic, visit www.hologic.com and connect with us on LinkedIn, Facebook, X, Instagram and YouTube.

Hologic and The Science of Sure are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.

About Gallup

Gallup delivers analytics and advice to help leaders and organizations solve their most pressing problems. Combining more than 80 years of experience with its global reach, Gallup knows more about the attitudes and behaviors of employees, customers, students and citizens than any other organization in the world.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250121461870/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye